492,540 Shares in Illumina, Inc. (NASDAQ:ILMN) Purchased by Nikko Asset Management Americas Inc.

Nikko Asset Management Americas Inc. acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 492,540 shares of the life sciences company's stock, valued at approximately $65,813,000. Nikko Asset Management Americas Inc. owned 0.31% of Illumina at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the stock. WCM Investment Management LLC grew its position in Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after purchasing an additional 27,618 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Illumina by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock worth $354,933,000 after purchasing an additional 48,018 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Illumina by 3.6% during the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock worth $328,158,000 after purchasing an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC lifted its holdings in Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after purchasing an additional 625,245 shares during the last quarter. 89.42% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Illumina Stock Up 3.4 %

Shares of Illumina stock traded up $2.87 during trading on Friday, reaching $87.66. The stock had a trading volume of 3,822,397 shares, compared to its average volume of 2,094,739. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.89 billion, a price-to-earnings ratio of -11.41, a P/E/G ratio of 1.60 and a beta of 1.17. The stock has a fifty day moving average price of $109.19 and a two-hundred day moving average price of $128.58. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last released its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on ILMN shares. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a research report on Friday, February 28th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Royal Bank of Canada reduced their price target on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating on the stock in a research report on Wednesday, March 12th. Stephens reissued an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Finally, TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and dropped their price objective for the stock from $177.00 to $140.00 in a research report on Friday, February 7th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.